Hetero, Gedeon Richter Join Hands for Commercialisation of Semaglutide Injection

New Delhi: Gedeon Richter and Hetero Labs today announce the signing of a global collaboration agreement for the joint development, registration, and commercialisation of Semaglutide Injection (generic of Ozempic), strengthening their long-term partnership and expanding access to affordable treatments for patients worldwide.

The agreement combines the companies’ complementary strengths under a coordinated global framework, with clearly defined territorial responsibilities and a balanced cost- and profit-sharing model. Operating through a joint governance structure, the partners ensure aligned decision-making and efficient execution.

Hetero has already made significant development investments, including technology setup and registration batch manufacturing. Regulatory filings are underway, with EU and US submissions planned for 2027. The collaboration leverages Hetero’s proven market reach within the United States and Emerging Markets, as well as Richter’s well-established commercial infrastructure across Europe and Central Asia, while maintaining optionality for future European manufacturing by Richter.

“This collaboration reflects the strong alignment, commitment, and shared pursuit of excellence between Hetero and Richter, forming a powerful partnership. It will enable us to deliver high‑quality, affordable therapies to patients living with diabetes and related cardiometabolic conditions worldwide.” said Dr. Bence Kovács, Global Head of General Medicines at Richter.

“We are delighted to collaborate with Richter, as our strategic partner for Semaglutide Injection. This strategic Partnership brings together the deep local expertise of Hetero and Richter to broaden the global access to Semaglutide Injection therapy” said Dr. Vamsi Krishna Bandi, Managing Director, Hetero Labs Ltd.